157 related articles for article (PubMed ID: 37530159)
21. Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway eosinophilia, and IL-5-expressing cells in Brown Norway rats.
Ihaku D; Cameron L; Suzuki M; Molet S; Martin J; Hamid Q
J Allergy Clin Immunol; 1999 Dec; 104(6):1147-54. PubMed ID: 10588994
[TBL] [Abstract][Full Text] [Related]
22. Effect of montelukast and MK-886 on hepatic ischemia-reperfusion injury in rats.
Daglar G; Karaca T; Yuksek YN; Gozalan U; Akbiyik F; Sokmensuer C; Gurel B; Kama NA
J Surg Res; 2009 May; 153(1):31-8. PubMed ID: 18656901
[TBL] [Abstract][Full Text] [Related]
23. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
[TBL] [Abstract][Full Text] [Related]
24. Montelukast does not protect against hyperoxia-induced inhibition of alveolarization in newborn rats.
Jouvencel P; Fayon M; Choukroun ML; Carles D; Montaudon D; Dumas E; Begueret H; Marthan R
Pediatr Pulmonol; 2003 Jun; 35(6):446-51. PubMed ID: 12746941
[TBL] [Abstract][Full Text] [Related]
25. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model.
Muz MH; Deveci F; Bulut Y; Ilhan N; Yekeler H; Turgut T
Exp Mol Med; 2006 Apr; 38(2):109-18. PubMed ID: 16672764
[TBL] [Abstract][Full Text] [Related]
26. Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury.
Erşahin M; Çevik Ö; Akakın D; Şener A; Özbay L; Yegen BC; Şener G
Prostaglandins Other Lipid Mediat; 2012 Dec; 99(3-4):131-9. PubMed ID: 22986158
[TBL] [Abstract][Full Text] [Related]
27. Cysteinyl leukotrienes predominantly mediate cisplatin-induced acute renal damage in male rats.
Hashim AA; Helmy MM; Mouneir SM
J Physiol Pharmacol; 2018 Oct; 69(5):. PubMed ID: 30683829
[TBL] [Abstract][Full Text] [Related]
28. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
29. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma.
Diamant Z; Grootendorst DC; Veselic-Charvat M; Timmers MC; De Smet M; Leff JA; Seidenberg BC; Zwinderman AH; Peszek I; Sterk PJ
Clin Exp Allergy; 1999 Jan; 29(1):42-51. PubMed ID: 10051701
[TBL] [Abstract][Full Text] [Related]
30. Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats.
Abdel-Raheem IT; Khedr NF
Naunyn Schmiedebergs Arch Pharmacol; 2014 Apr; 387(4):341-53. PubMed ID: 24363042
[TBL] [Abstract][Full Text] [Related]
31. Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication.
Muraki M; Imbe S; Sato R; Ikeda Y; Yamagata S; Iwanaga T; Tohda Y
Int Immunopharmacol; 2009 Oct; 9(11):1337-41. PubMed ID: 19706339
[TBL] [Abstract][Full Text] [Related]
32. Renal protective effects of leukotriene receptor blockers in an experimental model of cyclosporine nephrotoxicity.
Atakan A; Arikan H; Macunluoglu B; Tuglular S; Ulfer G; Cakalagaoglu F; Ozener C; Akoglu E
Transplant Proc; 2008; 40(1):279-84. PubMed ID: 18261606
[TBL] [Abstract][Full Text] [Related]
33. Concomitant activity of histamine and cysteinyl leukotrienes on porcine nasal mucosal vessels and nasal inflammation in the rat.
Lieber G; Jimenez J; Hunter JC; McLeod RL; Jia Y
Pharmacology; 2010; 85(5):311-8. PubMed ID: 20453555
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic potential of montelukast against mild colitis induced by dextran sulphate sodium in rats.
Holma R; Salmenperä P; Virtanen I; Vapaatalo H; Korpela R
J Physiol Pharmacol; 2007 Sep; 58(3):455-67. PubMed ID: 17928642
[TBL] [Abstract][Full Text] [Related]
35. Leukotriene receptor antagonism with montelukast as a possible therapeutic for venous thromboembolism prophylaxis: An observational study.
Sutton SS; Magagnoli J; Cummings TH; Hardin JW
Prostaglandins Other Lipid Mediat; 2022 Aug; 161():106649. PubMed ID: 35595009
[TBL] [Abstract][Full Text] [Related]
36. A leukotriene receptor antagonist modulates iNOS in the lung and in a leukotriene-free cell model.
Offer S; Shoseyov D; Bibi H; Eliraz A; Madar Z
Nitric Oxide; 2003 Aug; 9(1):10-7. PubMed ID: 14559427
[TBL] [Abstract][Full Text] [Related]
37. [The role of leukotrienes in inflammation and leukotriene inhibitors].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 1999 Sep; 7(39):85-93. PubMed ID: 10598480
[TBL] [Abstract][Full Text] [Related]
38. Montelukast in pediatric asthma management.
Walia M; Lodha R; Kabra SK
Indian J Pediatr; 2006 Apr; 73(4):275-82. PubMed ID: 16816486
[TBL] [Abstract][Full Text] [Related]
39. Gastroprotective effect of leukotriene receptor blocker montelukast in alendronat-induced lesions of the rat gastric mucosa.
Sener G; Kapucu C; Cetinel S; Cikler E; Ayanoğlu-Dülger G
Prostaglandins Leukot Essent Fatty Acids; 2005 Jan; 72(1):1-11. PubMed ID: 15589394
[TBL] [Abstract][Full Text] [Related]
40. Effect of Montelukast on Spinal Cord Ischemia- Reperfusion Injury.
Korkmaz K; Gedik HS; Budak AB; Yener AU; Kaya E; Genc SB; Cagli K
Turk Neurosurg; 2015; 25(5):757-65. PubMed ID: 26442542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
